1) Akaza H, Hinotsu S, Usami M, et al : Combined androgen blockade with bicalutamide for advanced prostate cancer : long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 115 : 3437—3445, 2009
2) Sweeney CJ, Chen YH, Carducci M, et al : Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373 : 737—746, 2015
3) James ND, de Bono JS, Spears MR, et al : Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 377 : 338—351, 2017
4) Fizazi K, Tran N, Fein L, et al : Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 377 : 352—360, 2017
5) Soloway MS, Hardeman SW, Hickey D, et al : Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61 : 195—202, 1998
6) Gandaglia G, Karakiewicz PI, Briganti A, et al : Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. Eur Urol 68 : 325—334, 2015
7) Yamada Y, Sakamoto S, Shimazaki J, et al : Significant prognostic difference between Grade Group 4 and 5 in the 2014 International Society of Urological Pathology Grading System for High Grade Prostate Cancer with Bone Metastasis. Prostate Int 5 : 143—148, 2017
8) Fukasawa S, Suzuki H, Sato F, et al : Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naïve prostate cancer (mHNPC) : Subgroup analysis of LATITUDE trial. J Clin Oncol 36 : 286, 2018
9) Matsuyama H, Shimabukuro T, Hara I, et al : Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer. Int J Clin Oncol 19 : 946—954, 2014
10) Parker CC, James ND, Brawley CD, et al : Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE) : a randomized controlled phase 3 trial Lancet. 2018 Oct 18 [Epub ahead of print]